^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-07209960

    i
    Other names: PF-07209960
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    PD1 inhibitor, IL-15R stimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Terminated, Pfizer | Completed --> Terminated; Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations
    Trial termination • Metastases
    |
    PF-07209960
    11ms
    Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> May 2023 | Trial primary completion date: Feb 2024 --> May 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    PF-07209960